Q2FY23 Preview: Sun Pharmaceutical Industries: Revenue seen at Rs111,933 million, PAT at Rs21,725 million

31 Oct 2022 , 06:46 AM

Result date: 1^st November, 2022
Recommendation: Add
Target price: Rs1,040
(Source: IIFL Research)

Sun Pharmaceutical Industries (Sun Pharma) could post ~17% growth in revenue over the year-ago quarter amid continued traction in its Specialty segment and domestic formulation business.

Sun Pharma’s EBITDA could grow 6.1% over the year-ago quarter, reflecting the strength in topline.

Consequently, the company’s Profit After Tax (PAT) could grow 4.2% over the year-ago quarter.

Important management insights to watch out for:
·         Outlook on margins
·         Update on new launches

Rs. Million	September 2022 estimates	QoQ change	YoY change
Revenue	111,933	4.6%	16.7%
EBITDA	30,042	7.2%	6.1%
Profit After Tax	21,725	5.5%	4.2%

Source: Brokerage Reports